




RealRate

PHARMACEUTICAL 2018

Dova Pharmaceuticals Inc
Rank 163 of 332



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Dova Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dova Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 119% points. The greatest weakness of Dova Pharmaceuticals Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 73% points.

The company's Economic Capital Ratio, given in the ranking table, is 273%, being 21% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	96,317
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	35,197
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1,000
Other Liabilities	0
Other Net Income	-746
Other Revenues	0
Property and Equipment	62
Research and Development	14,710
Selling, General and Administrative Expense	13,499

Output Variable	Value in 1000 USD
Assets	96,379
Liabilities	35,197
Expenses	29,209
Revenues	0
Stockholders Equity	61,182
Net Income	-29,955
Comprehensive Net Income	-29,955
BaseVar	80,766
ECR before LimitedLiability	157%
Economic Capital Ratio	273%